Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 13, 2007 Brian Lawler	Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note.
The Motley Fool July 12, 2007 Brian Lawler	Is It Time to Buy Genentech Yet? Genentech announces positive second-quarter results, but investors remain worried.
The Motley Fool April 14, 2008 Brian Lawler	Not a Bad Quarter for Genentech Two of its top drugs see speedy growth, but investors don't seem ecstatic about Genentech's first-quarter financial results.
The Motley Fool July 21, 2008 Brian Lawler	Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own.
The Motley Fool June 29, 2007 Brian Lawler	Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note.
The Motley Fool April 8, 2004 Brian Gorman	Genentech's Healthy Showing The company's first-quarter results were impressive, driven by pricey cancer drugs.
The Motley Fool January 12, 2007 Brian Lawler	Genentech on a Roll 2006 was a great year for the world's largest biotech firm. Investors should follow Genentech closely, as the company's a bellwether for the rest of the biopharmaceutical sector.
The Motley Fool July 15, 2008 Brian Lawler	Genentech Needs More Profit Power Another fine quarter of sales for the biotech company, but what about net earnings?
The Motley Fool January 15, 2008 Brian Lawler	Gauging Genentech Genentech releases its fourth-quarter results; in which revenues were up and adjusted earnings per share gained.
The Motley Fool July 12, 2005 Charly Travers	Genentech Shines On The world's largest biotech has been a four-bagger since 2003. Is it too late to get in the game?
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool June 13, 2008 Brian Lawler	Glaxo Gears Up a Blockbuster One of the pharmaceutical's top new compounds scores final EU approval.
The Motley Fool March 17, 2008 Brian Lawler	Genentech Takes Center Stage There might be more partnerships in store for this drugmaker.
The Motley Fool November 25, 2008 Brian Orelli	Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial.
The Motley Fool October 16, 2007 Brian Lawler	Genentech Fitting Better Cancer treatment Avastin continues to surge for the biopharma with a jump on the competition. Investors, take note.
The Motley Fool July 12, 2006 Stephen D. Simpson	Genentech's Deceptive Disappointment A slight shortfall in one product's sales is not a valid cause for panic. However, investors' patience might be wearing a bit thin here. What's more, Genentech's neither cheap nor undiscovered.
BusinessWeek July 31, 2006 Gene G. Marcial	Genentech Is More Robust Than It Looks Genentech, the world's second-largest biotech and an innovative developer of biotherapeutics, gets no favors from the Street.
The Motley Fool March 15, 2005 Charly Travers	The Best Company I've Never Owned The history of Genentech's Avastin, which just completed another phase 3 clinical trial showing that Avastin is effective in the treatment of non-small cell lung cancer. The author laments missing the opportunity to invest.
The Motley Fool February 25, 2008 Brian Lawler	A Positive Surprise for Genentech Biopharma Genentech's lead drug gets a conditional OK to treat breast cancer.
The Motley Fool January 11, 2006 Stephen D. Simpson	More Big, Boring Growth at Genentech The stock is expensive, and some may worry that Genentech didn't exceed estimates by as much as in the past.
The Motley Fool January 11, 2005 W.D. Crotty	Genentech's Pricey DNA The company continues to churn out sales and earnings gains, but it looks richly priced.
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
The Motley Fool August 27, 2007 Brian Lawler	Round 2 for Genentech Learn a lesson or two from Genentech's's dance with the FDA. The drugmaker's experience serves as a reminder of the fickle nature of the government agency, and the sometimes frustrating process of bringing a medication to market.
BusinessWeek January 12, 2004	Arthur Levinson The scientist-turned-CEO plans to move Genentech into the pharmaceutical big leagues.
The Motley Fool November 17, 2006 Brian Lawler	Genentech Gets Another Approval Today, Genentech finally received formal approval to market its breast cancer therapy Herceptin for the early stages. Investors, take note.
The Motley Fool April 30, 2008 Brian Lawler	A Tale of 2 DNA Drugs More trouble for Genentech's No. 2 product, the systemic lupus treatment Rituxan.
The Motley Fool September 11, 2006 Brian Lawler	More Work on Cancer Drug for Genentech The FDA asks for more data about Avastin, which could be used to treat various cancers. Investors, take note.
The Motley Fool July 8, 2004 Charly Travers	Genentech's Next Billion-Dollar Drug The cancer drug Avastin looks like a big winner. The market had exceptionally high expectations for this product, and it certainly seems well on its way to becoming a blockbuster drug.
The Motley Fool January 29, 2008 Brian Lawler	Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected.
The Motley Fool January 19, 2007 Stephen Albainy-Jenei	The Best Drug Stock for 2007: Genentech Now that growth is starting to level off for Genentech's four main oncology drugs, many analysts have lowered their ratings and cooled on Genentech's future. But the company is more than just a list of drugs.
The Motley Fool December 1, 2005 Brian Gorman	Glaxo Follows the Biotechs The company's new focus on cancer drugs looks like a good move. Investors, take note.
The Motley Fool December 6, 2007 Brian Lawler	Genentech Voted Down An FDA panel recommends against expanded use of Genentech's lead drug.
BusinessWeek October 6, 2003 Arlene Weintraub	Drug Development, Genentech Style Its promising colon cancer fighter Avastin is a prime example of how the biotech "keeps following the science."
The Motley Fool April 12, 2005 Brian Gorman	Genentech's Cancer Quest The company's achievements in lung cancer further strengthen its reputation as a cancer fighter. Would-be investors are best served by waiting patiently.
The Motley Fool April 12, 2006 Stephen D. Simpson	Genentech Is Weird Genentech is undoubtedly a great biotech, but it seems like Wall Street obsesses about the wrong things. Investors, take note.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.
The Motley Fool March 30, 2004 Charly Travers	Genentech: Priced for Perfection Can Genentech's earnings growth keep up with its valuation? The launch of three new products in the last nine months has made Genentech a very popular, and expensive, company.
Chemistry World July 2, 2014 Phillip Broadwith	Genentech to buy breast cancer specialist Seragon The deal gives Genentech access to Seragon's pipeline of investigational breast cancer therapies that work by destroying estrogen receptors on the surface of cancer cells.
The Motley Fool June 6, 2006 Brian Lawler	Exelixis' Continued Excellence The company reported preliminary phase 1 results for three of its lead compounds. Until investors see the results from phase 2 trials, they should chalk Exelixis up as a promising young biotech company whose successes they will patiently cheer for from the sidelines.
The Motley Fool April 24, 2007 Brian Lawler	Amgen On Sale? Biotech giant Amgen announces first-quarter financial results. Longer-term investors willing to wait for Amgen's drug pipeline to mature may be getting their chance to own a proven Ferrari at Ford prices.
The Motley Fool September 9, 2011 Frank Vinluan	GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche.
The Motley Fool May 29, 2007 Brian Lawler	Amgen Is Vexed The European Union medical authority says no to Amgen's cancer compound. Investors, take note.
The Motley Fool June 21, 2005 Brian Gorman	Genentech Hedges Its Edge The company's manufacturing capacity may allow it to attract biotech partners for years into the future. Investors, take note.
The Motley Fool February 27, 2004 Alyce Lomax	Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today.
The Motley Fool January 3, 2007 Brian Lawler	Exelixis Busy Selling Its Wares Exelixis inked another development deal with biopharma powerhouse Genentech. Investors, take note.
The Motley Fool May 2, 2007 Brian Lawler	Biogen's Measured Growth The biopharmaceutical reports first-quarter financial results. Investors, take note.
The Motley Fool January 25, 2007 Charly Travers	The Best Drug Stock for 2007 Is ... Is anyone surprised that the largest biotech company in the world, Genentech, came out on top?
The Motley Fool September 25, 2007 Billy Fisher	Bristol-Myers Buys In to Biologics Looking to advance its biologics strategy, Bristol-Myers Squibb announces it will acquire Adnexus Therapeutics, a privately held developer of biologics.
The Motley Fool July 9, 2008 Brian Lawler	Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests.
The Motley Fool October 1, 2008 Brian Orelli	3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear.